Azitra Completes $14 Million Series A Financing

FARMINGTON, Conn.–(BUSINESS WIRE)–Azitra Inc., a clinical-stage medical dermatology company addressing serious skin conditions by harnessing the microbiome, today announced that it has closed a $14 million Series A financing. The financing was led by KdT Ventures in conjunction with existing investor Bios Partners. Connecticut Innovations and Godfrey Capital also participated in the round. Proceeds from the financing will be used to expand the management team and to advance Azitra’s medical dermatology products in the clinic. This financing brings the total raised to date to $17 million.

“Our research continues to support the tremendous potential of our live biotherapeutic products to address multiple serious skin conditions and diseases. We believe we are just beginning to define the extraordinary potential of the microbiome to improve the health of skin,” said Richard Andrews, President and Chief Executive Officer. “We are grateful for this funding, which will allow us to expand our management team and advance our key products in the clinic in 2020. We have already initiated plans to execute a series of clinical studies with both our lead compound ATR-04 addressing cancer therapy associated skin rashes and ATR-02 to treat Netherton syndrome, an orphan skin disease.”

Azitra is focused on treating skin disease by combining the potential of the microbiome with state-of-the-art molecular genetics. The company’s product pipeline includes medical dermatology products to treat cancer therapy-associated skin rashes, Netherton syndrome, atopic dermatitis and ichthyosis vulgaris.

“We are thrilled to have co-led this round for Azitra and continue to be impressed with the power and breadth of the company’s proprietary platform,” said Cain McClary, Managing Partner, KdT Ventures. “We look forward to working with Azitra as they move their candidates into the clinic, building a deep portfolio of innovative medical dermatology compounds.”

“Azitra is on an a very exciting trajectory, and the Company is in the process of building out its team and research,” said Travis Whitfill, cofounder of Azitra and Partner at Bios Partners. “Bios Partners is proud to support Azitra, and we believe 2020 will be a transformative year for Azitra as the company begins to treat patients with debilitating skin diseases.”